These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 7751425)
1. Effect of food on the oral bioavailability of isosorbide-5-mononitrate administered as an extended-release tablet. Kosoglou T; Kazierad DJ; Schentag JJ; Patrick JE; Heimark L; Radwanski E; Christopher D; Flannery BE; Affrime MB J Clin Pharmacol; 1995 Feb; 35(2):151-8. PubMed ID: 7751425 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation. Kosoglou T; Patrick JE; Cohen A; Radwanski E; Christopher D; Affrime MB Clin Ther; 1995; 17(2):241-51. PubMed ID: 7614524 [TBL] [Abstract][Full Text] [Related]
3. Development of monolithic osmotic pump tablet system for isosorbide-5-mononitrate delivery and evaluation of it in vitro and in vivo. Duan X; Liu Q; Zhang Y; Bi K; Chen X; Wang Y; Luo G Drug Dev Ind Pharm; 2009 Apr; 35(4):499-507. PubMed ID: 18979308 [TBL] [Abstract][Full Text] [Related]
4. Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations. Chasseaud LF; Doyle E; Taylor T; Darragh A; Lambe RF Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):514-8. PubMed ID: 6642789 [TBL] [Abstract][Full Text] [Related]
5. The effect of food on the absorption of slow-release isosorbide-5-mononitrate tablets. Thomson AH; Miller SH; Green ST; Whiting B Eur J Clin Pharmacol; 1988; 34(1):47-50. PubMed ID: 3360048 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab). Stockis A; De Bruyn S; Deroubaix X; Jeanbaptiste B; Lebacq E; Nollevaux F; Poli G; Acerbi D Eur J Pharm Biopharm; 2002 Jan; 53(1):49-56. PubMed ID: 11777752 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of novel immediate-/controlled-release tablets of isosorbide-5-mononitrate (5-ISMN): in vitro-in vivo correlation. Li X; Jiang Q; Du L; Li Y; Li M Pharmazie; 2014 Feb; 69(2):109-16. PubMed ID: 24640599 [TBL] [Abstract][Full Text] [Related]
8. In vitro dissolution and in vivo bioequivalence evaluation of two brands of isosorbide 5-mononitrate sustained release tablets. Kim YH; Choi KS; Kam SH; Lee KH; Park JS Arzneimittelforschung; 2012 Dec; 62(12):576-82. PubMed ID: 23093481 [TBL] [Abstract][Full Text] [Related]
9. [Bioavailability of sustained-release and nonsustained-release isosorbide-5-mononitrate]. Muck B; Bonn R; Rietbrock N Arzneimittelforschung; 1989 Oct; 39(10):1274-6. PubMed ID: 2610720 [TBL] [Abstract][Full Text] [Related]
10. Isosorbide mononitrate 30% immediate-release 70% sustained-release formulation: a review. DUMQOL (DUtch Mononitrate Quality of Life) Study Group. Cleophas TJ; Niemeyer MG; Zwinderman AH; van der Wall EE Angiology; 2000 Aug; 51(8):631-8. PubMed ID: 10959515 [TBL] [Abstract][Full Text] [Related]
11. In vitro versus canine data for predicting input profiles of isosorbide-5-mononitrate from oral extended release products on a confidence interval basis. Fotaki N; Symillides M; Reppas C Eur J Pharm Sci; 2005 Jan; 24(1):115-22. PubMed ID: 15626585 [TBL] [Abstract][Full Text] [Related]
12. Influence of diet on the single-dose pharmacokinetics of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate. Sata H; Inoue K; Nii T; Kuroda T Biol Pharm Bull; 1997 Oct; 20(10):1111-5. PubMed ID: 9353575 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of three organic nitrates in Chinese healthy male volunteers. Chen J; Jiang XG; Cai L; Lu W; Gao KP; Shi ZQ; Zhang QZ Arzneimittelforschung; 2004; 54(4):203-6. PubMed ID: 15146932 [TBL] [Abstract][Full Text] [Related]
14. [Multiple dose pharmacokinetic and bioavailability studies of oral sustained release and conventional formulations of isosorbide-5-mononitrate in healthy volunteers]. Zhang Q; Huang X; Ji P; Fu L; Yan B; Wei S Yao Xue Xue Bao; 1998 May; 33(5):373-8. PubMed ID: 12017006 [TBL] [Abstract][Full Text] [Related]
16. Absorption of isosorbide-5-mononitrate at specific sites in the gastrointestinal tract. Kramer WG J Clin Pharmacol; 1994 Dec; 34(12):1218-21. PubMed ID: 7738218 [TBL] [Abstract][Full Text] [Related]
17. Sustained-release isosorbide mononitrate (50 mg): optimization of a once-daily dosage form for long-term treatment of angina pectoris. Bonn R Am J Cardiol; 1988 Mar; 61(9):12E-14E. PubMed ID: 3348135 [TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo evaluation of novel osmotic pump tablets of isosorbide-5-mononitrate containing polyvinyl pyrrolidone (PVP) for controlled release. Li X; Jiang Q; Du L; Wang C; Chi Q Pharmazie; 2012 Aug; 67(8):695-700. PubMed ID: 22957434 [TBL] [Abstract][Full Text] [Related]
19. [Comparative pharmacokinetics and bioavailability of isosorbide dinitrate and its metabolites isosorbide 5- and 2-mononitrate from delayed-release preparations]. Geigenberger A; Degen J; Maier-Lenz H Arzneimittelforschung; 1982; 32(9):1138-40. PubMed ID: 6890839 [TBL] [Abstract][Full Text] [Related]
20. Effect of extended-release isosorbide mononitrate one hour after dosing in patients with stable angina pectoris. IMDUR Study Group. Glasser SP Am J Cardiol; 1997 Dec; 80(12):1546-50. PubMed ID: 9416933 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]